Found 576 clinical trials
Dutch National Randomized Study: PSMA-PET/CT as a Triage Tool for Pelvic Lymph Node Dissection in Prostatectomy Patients
To determine if the use of Prostate-Specific Membrane Antigen Positron Emission Computer Tomography (PSMA PET/CT) as a selection tool for performing extended lymph node dissection (ePLND) for
- 0 views
- 25 Aug, 2021
- 1 location
Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence
This study evaluates the value of Gallium-68 labeled PSMA (68Ga-PSMA) for PET/CT imaging of prostate cancer recurrence. 68Ga-PSMA is a radioactive molecule, which binds to prostate cancer cells
- 0 views
- 26 Feb, 2022
- 1 location
Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection (GuideView)
histopathology assessments. Approximately 195 participants will be enrolled to ensure that at least 156 participants are evaluable (i.e. have both an evaluable PET/CT scan and histopathology assessment
- 0 views
- 23 Jul, 2022
- 10 locations
Screening for Cancer in Patients With Unprovoked VTE
Open and multicenter randomized clinical trial (1:1) comparing limited screening with extended screening with the performance of Positron emission tomography-computed tomography (PET-CT) scan in
- 0 views
- 18 Dec, 2021
- 9 locations
Dose-Reduced Consolidation Radiation Therapy in Patients With Diffuse Large B-cell Lymphoma (DLBCL)
> Hypothesis: The radiation dose and treatment volume can be safely reduced from 30 Gy to 20 Gy while maintaining high rates of local control in patients who had a negative PET-CT scan following rituximab
- 8 views
- 27 Jul, 2022
- 13 locations
Brentuximab Vedotin in Early Stage Hodgkin Lymphoma (RADAR)
Eligible patients will be randomised to receive either ABVD or A2VD chemotherapy. An interim PET-CT scan will be performed after 2 cycles of treatment, which will be used to adapt
- 2 views
- 09 Jun, 2022
- 7 locations
Multicentric Comparative Study Between a Conventional and an Intensive Follow up Strategy After Treatment of a Head and Neck Squamous Cell Carcinoma (SURVEILL'ORL)
imaging including PET-CT for patients N2) performed 2 to 4 months after the end of treatment. The randomization ratio is 1:1.
- 0 views
- 03 Mar, 2022
Screening for Occult Malignancy in Patients With Unprovoked Venous Thromboembolism (MVTEP2/SOME2)
occult cancer especially based on FDG PET/CT, and suggests that the best target population for cancer screening would be patients with unprovoked VTE older than 50 years of age (6.7% in patients aged 50
- 26 views
- 22 Mar, 2022
- 15 locations
18F-DOPA II - PET Imaging Optimization
A single centre non-randomized, non-blinded phase III prospective cohort study of 18F-DOPA PET/CT imaging in specific patient populations: Pediatric patients (less than 18 years
- 8 views
- 03 May, 2022
- 1 location
Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors
PET/CT) can further detect tumors. Eligibility People ages 12 and older with VHL that causes tumors and cysts to grow in the pancreas Design
- 0 views
- 29 Jul, 2022
- 1 location